GlaxoSmithKline halted its development program of SRT501, a special formulation of resveratrol which is reported to be the active ingredient from red wine, touted as an anti-ageing treatment. GSK obtained the right to develop the compound from Cambridge, Mass.-based Sirtris in 2008 with a $720 million package ...

The US Food and Drug Administration has declined to approve Valeant and GlaxoSmithKline's ezogabine (Potiga), an investigational epilepsy medication intended as an adjunctive therapy for adults with partial-onset seizures. The agency’s Center for Drug Evaluation and Research issued ...

GlaxoSmithKline is putting some added financial muscle into its embrace of South San Francisco-based Theravance. The pharma giant is investing close to $130 million to boost its stake in its biotech partner to 19 percent. GSK and Theravance are allied ...

Benlysta one step closer to become a blockbuster An FDA advisory committee voted Tuesday 13 to 2 in favor of approval of  Human Genome Sciences Inc's Benlysta (belimumab) as a treatment for adults with systemic lupus erythematosus (SLE), a chronic debilitating ...

Human Genome Sciences' ($HGSI) lupus drug Benlysta has the potential to be the first lupus treatment approved in more than 50 years, as well as the first developed specifically for the autoimmune disease. Bloomberg's analysts believe that Benlysta, onc...

FDA to review GSK's response for Horizant XenoPort, the Santa Clara, CA-based company, announced that it had revised its development agreement  with the UK pharma giant GSK on the new therapy for restless leg syndrome (RLS). The drug developer said in a ...

Continuing its push into the rare disease market, GlaxoSmithKline has agreed to pay $60 million up front and up to $170 million in milestone payments for Amicus Therapeutics' Fabry disease drug Amigal (migalastat HCl). Fabry is an inherited d...

The swiss drug maker Novartis says that its experimental asthma and chronic obstructive pulmonary disease (COPD) therapy QMF149 will be delayed, and the planned filing will be pushed back to 2014 or later. The original plan had been to file the drug in 2013.

The UK pharma giant GlaxoSmithKline has formed a strategic alliance with Fondazione Telethon and Fondazione San Raffaele, one of the biggest biomedical charities in Italy and the country’s largest private research institute, targeting novel treatments for rare genetic disorders. The ...

Emboldened by recent talks with regulators, Denmark's Genmab says its cancer drug zalutumumab looks like its nearing the point at which it can be filed for an approval in Europe. But it looks like the FDA will need new studies costing hundred...